Aytu Biopharma, Inc.
AYTU
$2.19
$0.063.02%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -8.24% | -17.98% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -8.24% | -17.98% | |||
| Cost of Revenue | -3.67% | -13.55% | |||
| Gross Profit | -10.42% | -19.93% | |||
| SG&A Expenses | 20.87% | -8.88% | |||
| Depreciation & Amortization | -51.79% | 0.11% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.19% | -9.58% | |||
| Operating Income | -335.00% | -73.56% | |||
| Income Before Tax | 110.11% | -609.25% | |||
| Income Tax Expenses | -- | 458.20% | |||
| Earnings from Continuing Operations | 109.88% | -604.57% | |||
| Earnings from Discontinued Operations | -- | 14.81% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 109.92% | -596.19% | |||
| EBIT | -335.00% | -73.56% | |||
| EBITDA | -136.25% | -48.26% | |||
| EPS Basic | 107.13% | -548.16% | |||
| Normalized Basic EPS | 112.64% | -364.50% | |||
| EPS Diluted | 97.35% | -1,512.39% | |||
| Normalized Diluted EPS | 106.13% | -453.82% | |||
| Average Basic Shares Outstanding | 39.01% | 10.71% | |||
| Average Diluted Shares Outstanding | 186.78% | -17.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||